C. M. White

发表

Preventing a New Tuskegee: Food and Drug Administration Oversight of Overseas Research Must Match That in the United States

C. M. White, L. White, 2021, Journal of clinical pharmacology.

Inclisiran: A Novel Small Interfering RNA Drug for Low‐Density Lipoprotein Reduction

C. M. White, Kimberly W Smith, 2022, Journal of clinical pharmacology.

A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin

C. M. White, 2002, Journal of clinical pharmacology.

Criminal Action Against Drug Counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 Through 2021

C. M. White, 2022, The Annals of pharmacotherapy.

Continued Risk of Dietary Supplements Adulterated With Approved and Unapproved Drugs: Assessment of the US Food and Drug Administration's Tainted Supplements Database 2007 Through 2021

C. M. White, 2022, Journal of clinical pharmacology.

The Morality of National Defense: An Aristotelian-Thomist Account

C. M. White, 2017 .

Evaluation of the Antihyperlipidemic Properties of Dietary Supplements

C. White, C. M. White, Michael F. Caron, 2001, Pharmacotherapy.

A Review of Pathophysiology and Therapy of Patients with Vasovagal Syncope

C. White, J. Tsikouris, C. M. White, 2000, Pharmacotherapy.

Pharmacological Effects of HMG CoA Reductase Inhibitors Other Than Lipoprotein Modulation

C. M. White, 1999, Journal of clinical pharmacology.

A Review of Potential Cardiovascular Uses of Intravenous Glucagon Administration

C. M. White, 1999, Journal of clinical pharmacology.

Anemia Management in Heart Failure: A Thick Review of Thin Data

C. White, B. McBride, C. M. White, 2004, Pharmacotherapy.

The Effect of Pharmacokinetically Guided Acute Intravenous Testosterone Administration on Electrocardiographic and Blood Pressure Variables

P. Thompson, G. Heller, N. Moyna, 1999, Journal of clinical pharmacology.

Response to Letter to the Editor by Dr Robinson

C. M. White, L. White, 2021, Journal of clinical pharmacology.

Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis.

V. Pasupuleti, C. M. White, J. Hwang, 2023, Journal of dietary supplements.

Evaluation of CYP2D6 Oxidation of Dextromethorphan and Propafenone in a Chinese Population with Atrial Fibrillation

M. Chow, Chengde Fan, C. M. White, 2001, Journal of clinical pharmacology.

Psychedelics for Patients With Cancer: A Comprehensive Literature Review.

C. M. White, Nissen D Weisman, Joseph D Dalo, 2023, The Annals of pharmacotherapy.

Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19

C. White, J. J. Barboza, Adrian V. Hernández, 2020, Annals of Internal Medicine.

Should an LDL-Cholesterol Target–Based Approach Be Readopted?

C. White, C. M. White, E. Nguyen, 2018, The Annals of pharmacotherapy.

Understanding and Preventing (N-Nitrosodimethylamine) NDMA Contamination of Medications

C. White, C. M. White, 2019, The Annals of pharmacotherapy.

Role of Ivabradine in the Treatment of Patients With Cardiovascular Disease

C. White, C. M. White, E. Nguyen, 2016, The Annals of pharmacotherapy.

Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows

A. Nafziger, C. M. White, C. M. White, 2021, Journal of clinical pharmacology.